Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
Age
4–16
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pediatric subjects (4 - 16 years old) diagnosed with refractory partial onset seizures for a minimum of six months prior to Visit 1 experiencing at least two partial onset seizures during the four weeks prior to Visit 1 will be enrolled
Subjects should be on a stable regimen of one or a maximum of two other antiepileptic drugs (AEDs) for at least 2 weeks prior to Visit 1
Subject must have an Intelligence Quotient (IQ) as assessed during Visit 1 of at least 70
Subject and parent/guardian should be fluent in English
You may not be if
Subject must not have had previous treatment with levetiracetam unless, in the opinion of the investigator, the subject's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of levetiracetam was confounded by concomitant medication
Subject is receiving benzodiazepines on a routine or chronic basic and is unable to discontinue use four weeks prior to Visit 1
Subject has seizures too close together to accurately count
Subject has a current psychiatric disorder other than mild to moderate attention deficit, behavior, or learning disorders
Clareo Health | A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
